Evidence map›Paper›PMID 30474162›Full record

ArticleAddiction (Abingdon, England)2019

Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point.

Brian D Kiluk, Garrett M Fitzmaurice, Eric C Strain, Roger D Weiss

Abstract readComment
In one paragraph

Article in Addiction (Abingdon, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Brian D KilukDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-1175-7979
Garrett M FitzmauriceDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA.
Eric C StrainDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Roger D WeissDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA.

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
Identification of a Meaningful Cocaine Use Outcome MeasureR33DA041661 · NIDA · YALE UNIVERSITY · PI KILUK, BRIAN D. · 2018 to 2020
$1.1M
Reduction in frequency of drug use as a primary outcome and its relation to changes in health-related and other functional outcomes in stimulant use disorder trialsR21DA042847 · NIDA · MCLEAN HOSPITAL · PI FITZMAURICE, GARRETT M · 2016 to 2017
$476k
Identification of a Meaningful Cocaine Use Outcome MeasureR21DA041661 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M., KILUK, BRIAN D. · 2016 to 2017
$456k
NIDA NIH HHS K24 DA022288NIDA NIH HHS R21 DA041661NIDA NIH HHS R21 DA042847NIDA NIH HHS R33 DA041661NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Substance-Related DisordersHumansClinically meaningful outcomeDSM-5functioningnegative consequencessubstance use disorderstreatment end-point

Identifiers

PMID30474162
PMCPMC6357767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.